Background In 2010, 1% of our pharmaceutical expenditure corresponded to off-label use, except for cytostatics. The dermatology department has increased drug costs due to the off-label use.
Purpose To assess the applications and costs of off-label drug use in dermatology. To check the therapeutic results obtained and the number of available reports.
Materials and methods The authors reviewed off-label requests from Dermatology during 2009 and 2010. The authors reviewed the reports compiled in Medline from 1997 to 2010 and classified according to reported cases number in N < 10, N between 10 and 50, N between 51 and 100, and N>100. The results were classified as effective if dermatologists achieved the therapeutic objective, partially effective if they reached the initial objective at least in 50% and ineffective when they didn't achieved the therapeutic purpose.
Results In 2009, 95 drugs were requested for an off-label use representing 404,909 €; 7 were requests from Dermatology at a cost of 49,218 €. In 2010, 134 drugs were requested for off-label use representing 410,716 €; 5 were requests from Dermatology represented 117,565 €.
Conclusions During 2010 there was an increase in the cost of off-label use in dermatology due to lenalidomide. Half of the treatments were effective, 25% partially effective and 25% ineffective. One third of the requests were supported by fewer than 10 reported cases.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.